E-DRUG: COVID-19 and Dexamethasone A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection
--------------------------------------------------------------------------
July 30, 2020
COVID-19 and Dexamethasone
A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection
William M. Stauffer, MD, MSPH1,2; Jonathan D. Alpern, MD3,4; Patricia F. Walker, MD, DTM&H2,3
Author Affiliations Article Information
JAMA. Published online July 30, 2020. doi:10.1001/jama.2020.13170
https://jamanetwork.com/journals/jama/fullarticle/2769100
A widely publicized press release and subsequent preliminary report of the RECOVERY trial, a randomized study conducted in the UK, noted a survival benefit with the use of dexamethasone in hospitalized patients with coronavirus disease 2019 (COVID-19).1 The use of dexamethasone for management of COVID-19 has already increased, particularly given the recent National Institutes of Health COVID-19 Treatment Panel guidelines that recommend its use.2
Although clinicians are familiar with the most common adverse effects associated with dexamethasone, a corticosteroid, they may be less familiar with a potentially severe, but preventable, less common complication: Strongyloides hyperinfection or dissemination syndrome (hyperinfection).3
read more
https://jamanetwork.com/journals/jama/fullarticle/2769100
Carinne Bruneton E-Med
Carinne Bruneton <carinne.bruneton@hotmail.fr>